The Japan Times - Moderna says US refusing to review mRNA-based flu shot

EUR -
AED 4.199928
AFN 73.181618
ALL 94.106337
AMD 421.027097
ANG 2.047263
AOA 1049.127837
ARS 1702.605321
AUD 1.652633
AWG 2.061095
AZN 1.946005
BAM 1.959664
BBD 2.302731
BDT 140.966124
BGN 1.933462
BHD 0.431099
BIF 3413.242466
BMD 1.143465
BND 1.47911
BOB 7.917543
BRL 5.970377
BSD 1.143249
BTN 109.125801
BWP 15.504438
BYN 3.316811
BYR 22411.910329
BZD 2.299424
CAD 1.621833
CDF 2568.22166
CHF 0.918771
CLF 0.026886
CLP 1058.146865
CNY 7.763099
CNH 7.760577
COP 3848.616693
CRC 520.323758
CUC 1.143465
CUP 30.301818
CVE 110.744057
CZK 24.19057
DJF 203.216727
DKK 7.474641
DOP 67.580428
DZD 152.451308
EGP 56.130747
ERN 17.151972
ETB 180.778811
FJD 2.584745
FKP 0.861174
GBP 0.856627
GEL 3.013033
GGP 0.861174
GHS 13.041167
GIP 0.861174
GMD 82.903417
GNF 10033.903442
GTQ 8.722085
GYD 239.150538
HKD 8.967794
HNL 30.027263
HRK 7.535091
HTG 149.543579
HUF 354.34256
IDR 20542.345361
ILS 3.423134
IMP 0.861174
INR 109.200947
IQD 1498.510637
IRR 1573350.408782
ISK 143.687923
JEP 0.861174
JMD 179.564085
JOD 0.81074
JPY 184.172205
KES 147.827575
KGS 99.995782
KHR 4585.293614
KMF 492.833097
KPW 1029.118732
KRW 1760.26087
KWD 0.349077
KYD 0.95277
KZT 542.865736
LAK 25236.268378
LBP 102397.273656
LKR 383.73999
LRD 207.824993
LSL 18.604103
LTL 3.376354
LVL 0.691671
LYD 7.335349
MAD 10.727417
MDL 20.24775
MGA 4894.029749
MKD 61.639599
MMK 2400.426399
MNT 4098.39481
MOP 9.236633
MRU 45.807476
MUR 54.051187
MVR 17.678177
MWK 1986.198168
MXN 19.987195
MYR 4.665448
MZN 73.079179
NAD 18.62733
NGN 1566.891174
NIO 41.833669
NOK 11.261966
NPR 174.604541
NZD 2.008284
OMR 0.439658
PAB 1.143244
PEN 3.890049
PGK 5.019237
PHP 70.349964
PKR 318.026184
PLN 4.288448
PYG 6947.700258
QAR 4.167887
RON 5.234323
RSD 117.377832
RUB 88.613798
RWF 1675.175951
SAR 4.307662
SBD 9.214658
SCR 15.427597
SDG 686.65423
SEK 11.06508
SGD 1.47839
SHP 0.853712
SLE 27.843524
SLL 23977.889581
SOS 653.492461
SRD 43.048029
STD 23667.412977
STN 24.927533
SVC 10.003726
SYP 126.389564
SZL 18.603504
THB 37.960254
TJS 10.575408
TMT 4.013561
TND 3.346348
TOP 2.753189
TRY 53.412047
TTD 7.756261
TWD 36.485447
TZS 3001.725542
UAH 51.234476
UGX 4190.244474
USD 1.143465
UYU 45.889889
UZS 13624.382847
VES 730.563408
VND 30061.689927
VUV 137.212488
WST 3.166992
XAF 657.250166
XAG 0.018763
XAU 0.000277
XCD 3.090271
XCG 2.060427
XDR 0.817598
XOF 656.965407
XPF 119.331742
YER 271.057928
ZAR 18.602583
ZMK 10292.559186
ZMW 20.835904
ZWL 368.195203
  • CMSC

    0.0400

    21.99

    +0.18%

  • BCC

    0.4500

    75.93

    +0.59%

  • JRI

    0.0600

    13

    +0.46%

  • GSK

    2.3600

    53.66

    +4.4%

  • CMSD

    -0.0300

    22.15

    -0.14%

  • RBGPF

    0.0000

    65.61

    0%

  • NGG

    2.6700

    82.85

    +3.22%

  • BCE

    0.4000

    21.42

    +1.87%

  • BTI

    1.2100

    61.77

    +1.96%

  • RIO

    1.0700

    94.42

    +1.13%

  • RYCEF

    0.2500

    19.75

    +1.27%

  • BP

    1.2500

    37.4

    +3.34%

  • AZN

    11.2900

    195.15

    +5.79%

  • RELX

    0.5500

    31.93

    +1.72%

  • VOD

    0.1400

    13.15

    +1.06%

Moderna says US refusing to review mRNA-based flu shot
Moderna says US refusing to review mRNA-based flu shot / Photo: JEAN-FRANCOIS MONIER - AFP

Moderna says US refusing to review mRNA-based flu shot

Vaccine manufacturer Moderna said Tuesday the US Food and Drug Administration was refusing to review an application for its first mRNA-based flu shot.

Text size:

The move comes as the current iteration of the FDA has called for a reconsideration of approval procedures for certain vaccines, including for influenza -- proposed federal policy changes under President Donald Trump that have triggered widespread alarm among public health and medical professionals.

Moderna, a US company, said the agency's top vaccine regulator, Vinay Prasad, wrote in a letter that Moderna's clinical trial was not "adequate and well-controlled," and had not tested its experimental shot against the best product on the market.

In the large trial Moderna had compared its new vaccine with Fluarix, an approved flu shot from the company GSK.

Moderna said the rejection was "inconsistent with previous written communications" with the FDA branch that regulates biological products, including vaccines, known by the acronym CBER.

The decision "did not identify any safety or efficacy concerns with our product" and "does not further our shared goal of enhancing America's leadership in developing innovative medicines," Moderna CEO Stephane Bancel said in the statement.

"It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting."

Moderna said it had received a Refusal-to-File letter, which would indicate the application did not meet the requirements for substantive review. The company said it had requested a meeting to discuss the decision.

The letter did not identify any safety or efficacy concerns regarding the mRNA vaccine, said Moderna, which added the shot was accepted for review in the European Union, Canada and Australia.

During his first term Trump called mRNA technology a "modern-day miracle."

It was used during the Covid-19 pandemic to swiftly develop an immunization against the fast-spreading illness, and was credited with saving millions of lives.

Vaccines against Covid-19 are considered safe and effective by global health authorities, and protect against the most severe forms of the infection.

But in his second term, Trump has appointed Robert F. Kennedy Jr as his health chief, and the long-time vocal vaccine skeptic has spent the past year reshaping federal health agencies in his image.

That has meant spreading false information and sowing doubt about the safety and efficacy of vaccines widely known to be safe, and upending the pediatric immunization schedule.

Notably, Kennedy cut off federal research grants that funded mRNA development.

S.Suzuki--JT